Letter

Europe also needs agency for postmarketing surveillance

BMJ 2005; 330 doi: 10.1136/bmj.330.7490.540 (Published 3 March 2005)
Cite this as: BMJ 2005;330:540.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Silvio Garattini, director (garattini@marionegri.it)
  1. Istituto di Ricerche Farmacologiche “Mario Negri,” Via Eritrea, 62, I-20157 Milan

    EDITOR—With respect to the withdrawal of rofecoxib (Vioxx), several months of debate on drug safety have focused on US policy, but very little has been said about the European situation.1 Some fundamental questions remain to be answered. For example, why did the manufacturer, and not the regulatory agencies, withdraw rofecoxib?

    Both the US Food and Drug …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular